Peanut allergy has emerged as one of the most striking public health puzzles of the past three decades, now affecting up to 5 percent of children in parts of the United States and nearly tripling in prevalence since the 1990s. For families, the diagnosis ushers in a life of constant vigilance—carrying epinephrine auto-injectors, scrutinizing food labels, and navigating a world where trace exposures can trigger anaphylaxis. Clinicians have recently gained powerful new tools, including FDA-approved oral immunotherapy and the monoclonal antibody omalizumab, but they remain unable to answer a deeply frustrating question: why does the very same desensitization protocol produce robust tolerance in one patient yet fail in another? A sweeping new initiative at the Icahn School of Medicine at Mount Sinai aims to unravel that mystery by mapping the immune system’s trajectory through treatment at unprecedented resolution.
The National Institute of Allergy and Infectious Diseases has awarded Mount Sinai a five-year, $7.2 million grant to establish a new Asthma and Allergic Diseases Cooperative Research Center dedicated to precision medicine for peanut allergy. Dubbed INROADS—Immunologic Trajectories of Peanut Desensitization—the center will bring together experts in allergy, immunology, multi-omics, artificial intelligence, and computational biology to identify the biological signatures that distinguish a successful desensitization from a disappointing outcome. Lead investigator Supinda Bunyavanich, Deputy Director of the Elliot and Roslyn Jaffe Food Allergy Institute, believes the moment is ripe to move beyond trial-and-error approaches. “This new center allows us to take the next critical step toward precision medicine by identifying the immune and molecular pathways that determine treatment success,” she said. “Our goal is to help ensure that every patient receives the therapy most likely to benefit them.”
At the heart of INROADS lie two ambitious research projects designed to capture complementary layers of immune information. The first, MICRO-TRACK, will perform deep immune profiling on blood samples and nasal epithelial cells collected from children and adults undergoing controlled desensitization. Using mass cytometry, allergen-specific tetramer staining to identify rare peanut-reactive T cells, and functional assays that measure regulatory T cell activity, the team plans to track how the frequencies and phenotypes of effector and regulatory lymphocyte populations shift over time. Parallel in vitro models will allow the researchers to test whether specific cytokine milieus or cell-cell interactions are necessary for the induction of sustained unresponsiveness. The goal is to move beyond simple IgE measurements and instead build a dynamic atlas of the cellular networks that either license or block tolerance to peanut allergens.
The second project, SPADE, will apply transcriptomic and machine learning approaches to discover molecular signatures of desensitization. By sequencing RNA from peripheral blood mononuclear cells at multiple timepoints before, during, and after oral immunotherapy, investigators will search for gene expression patterns correlated with clinical outcomes. Advanced algorithms, including regularized regression models and ensemble classifiers, will be trained to distinguish eventual responders from nonresponders using only pre-treatment transcriptomic data—essentially creating a molecular crystal ball. Such a tool, if validated, could one day be deployed in the clinic to guide treatment selection, sparing patients unlikely to benefit from prolonged, burdensome desensitization regimens.
Crucially, the center’s design acknowledges that high-dimensional biological data are only as valuable as the clinical context in which they are embedded. The PATHWAYS Clinical Core will coordinate carefully phenotyped cohorts, collecting samples and standardized outcomes from oral food challenges—the gold-standard diagnostic test—administered before and after desensitization therapies. This ensures that every transcriptomic and proteomic datapoint can be anchored to a real-world endpoint, whether that is the cumulative tolerated dose of peanut protein or the development of sustained unresponsiveness after therapy is paused. A separate Data Stewardship Core will curate the resulting multi-omics dataset—one of the richest ever assembled for food allergy—and make it openly available to the broader research community, accelerating discovery far beyond Mount Sinai.
The initiative builds on decades of pivotal peanut allergy research at the institution. Mount Sinai investigators contributed to the landmark clinical trials that led to FDA approval of both peanut oral immunotherapy and omalizumab, and they recently upended conventional wisdom by showing that with precise characterization of an individual’s sensitivity threshold, many patients can be safely desensitized using measured doses of store-bought peanut products. Scott H. Sicherer, Director of the Jaffe Food Allergy Institute and a multiple principal investigator on the grant, notes that these advances have only sharpened the need for predictive biomarkers. “The discoveries generated through this center have the potential to fundamentally improve how we deliver desensitization therapies, making them more personalized, more effective, and ultimately more accessible for patients and families,” he said.
Other key faculty include Erik Wambre, whose work on allergen-specific T cell signatures has redefined how the field conceptualizes the allergic response; Julie Wang, a leader in pediatric food allergy trials; statistician and machine learning expert Pei Wang; core facility directors Kristin Beaumont and Seung-Hee Kim-Schulze; and additional investigators spanning the Departments of Pediatrics, Genetics and Genomic Sciences, and Immunology and Immunotherapy. Together, they intend not only to produce clinically actionable biomarkers but also to illuminate fundamental mechanisms of immune regulation that could be harnessed for other food allergies, such as those to milk, egg, and tree nuts, as well as for allergic diseases more broadly.
The INROADS center is funded through the NIAID Asthma and Allergic Diseases Cooperative Research Centers program, a network designed to catalyze exactly this kind of transdisciplinary science. By fusing granular immune monitoring with computational modeling, the team hopes to transform peanut allergy desensitization from a blunt instrument into a finely tuned, evidence-based intervention. For the millions of individuals who navigate the daily precariousness of a life-threatening food allergy, that shift cannot come soon enough.
Subject of Research: Identification of immunological biomarkers and molecular pathways that predict clinical response to peanut allergy desensitization therapies using advanced immune profiling, transcriptomics, and machine learning.
Article Title: Decoding Peanut Allergy Desensitization: A $7.2 Million Push to Personalize a Life-Saving Treatment
News Publication Date: July 7, 2026
Web References: https://profiles.mountsinai.org/supinda-bunyavanich; https://profiles.mountsinai.org/scott-h-sicherer
Image Credits: None
Keywords: peanut allergy, oral immunotherapy, omalizumab, desensitization, biomarkers, precision medicine, machine learning, transcriptomics, immunology, systems biology, INROADS, Mount Sinai
